Sorel Muresan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sorel Muresan has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Southan
Institute for Neuroscience and Cardiovascular Research University of Edinburgh Edinburgh EH8 9XD UK
5 shared publications - Christian Tyrchan
AstraZeneca (Sweden)
4 shared publications Thierry Kogej
4 shared publications- Ola Engkvist
Discovery Sciences, Molecular AI, AstraZeneca R&D
3 shared publications Anders Backlund
Department of Medicinal Chemistry, Division of Pharmacognosy, BMC, Uppsala University, Box 574, S-751 23 Uppsala, Sweden, Pharmnovo Inc., Sahlgrenska Science Park, S-413 46 Gothenburg, Sweden, DECS Global Compound Sciences, AstraZeneca R&D, S-431 83 Mölndal, Sweden, and Division of Biocomputing, MSC11 6145, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131
2 shared publicationsHerry H. Nijhuis
Agrotechnological Research Institute (ATO-DLO), Food and Food Processing Division, PO Box 17, NL-6700 AA Wageningen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 13 December 2012
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 4 (1) , 35
Consistency of systematic chemical identifiers within and between small-molecule databases
Correctness of structures and associated metadata within public and commercial chemical databases greatly impacts drug discovery research activities such as quantitative structure–property relationships modelling and compound novelty checking. MOL files, SMILES notations, IUPAC names, and InChI strings are ubiquitous file formats and systematic identifiers for chemical structures. While interchangeable for many cheminformatics purposes there have been no studies on the inconsistency of these structure identifiers due to various approaches for data integration, including the use of different software and different rules for structure standardisation. We have investigated the consistency of systematic identifiers of small molecules within and between some of the commonly used chemical resources, with and without structure standardisation.
- 13 December 2012
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 4 (1) , 35
Open AccessConsistency of systematic chemical identifiers within and between small-molecule databases
Correctness of structures and associated metadata within public and commercial chemical databases greatly impacts drug discovery research activities such as quantitative structure–property relationships modelling and compound novelty checking. MOL files, SMILES notations, IUPAC names, and InChI strings are ubiquitous file formats and systematic identifiers for chemical structures. While interchangeable for many cheminformatics purposes there have been no studies on the inconsistency of these structure identifiers due to various approaches for data integration, including the use of different software and different rules for structure standardisation. We have investigated the consistency of systematic identifiers of small molecules within and between some of the commonly used chemical resources, with and without structure standardisation.
- 18 June 2012
- Published by Springer Nature
- Vol. 910, 145-164
Mapping Between Databases of Compounds and Protein Targets
Databases that provide links between bioactive compounds and their protein targets are increasingly important in drug discovery and chemical biology. They join the expanding universes of cheminformatics via chemical structures on the one hand and bioinformatics via sequences on the other. However, it is difficult to assess the relative utility of databases without the explicit comparison of content. We have exemplified an approach to this by comparing resources that each has a different focus on bioactive chemistry (ChEMBL, DrugBank, Human Metabolome Database, and Therapeutic Target Database) both at the chemical structure and protein levels. We compared the compound sets at different representational stringencies using NCI/CADD Structure Identifiers. The overlap and uniqueness in chemical content can be broadly interpreted in the context of different data capture strategies. However, we recorded apparent anomalies, such as many compounds-in-common between the metabolite and drug databases. We also compared the content of sequences mapped to the compounds via their UniProt protein identifiers. While these were also generally interpretable in the context of individual databases we discerned differences in coverage and the types of supporting data used. For example, the target concept is applied differently between DrugBank and the Therapeutic Target Database. In ChEMBL it encompasses a broader range of mappings from chemical biology and species orthologue cross-screening in addition to drug targets per se. Our analysis should assist users not only in exploiting the synergies between these four high-value resources but also in assessing the utility of other databases at the interface of chemistry and biology.
- 18 June 2012
- Published by Springer Nature
- Vol. 910, 145-164
Mapping Between Databases of Compounds and Protein Targets
Databases that provide links between bioactive compounds and their protein targets are increasingly important in drug discovery and chemical biology. They join the expanding universes of cheminformatics via chemical structures on the one hand and bioinformatics via sequences on the other. However, it is difficult to assess the relative utility of databases without the explicit comparison of content. We have exemplified an approach to this by comparing resources that each has a different focus on bioactive chemistry (ChEMBL, DrugBank, Human Metabolome Database, and Therapeutic Target Database) both at the chemical structure and protein levels. We compared the compound sets at different representational stringencies using NCI/CADD Structure Identifiers. The overlap and uniqueness in chemical content can be broadly interpreted in the context of different data capture strategies. However, we recorded apparent anomalies, such as many compounds-in-common between the metabolite and drug databases. We also compared the content of sequences mapped to the compounds via their UniProt protein identifiers. While these were also generally interpretable in the context of individual databases we discerned differences in coverage and the types of supporting data used. For example, the target concept is applied differently between DrugBank and the Therapeutic Target Database. In ChEMBL it encompasses a broader range of mappings from chemical biology and species orthologue cross-screening in addition to drug targets per se. Our analysis should assist users not only in exploiting the synergies between these four high-value resources but also in assessing the utility of other databases at the interface of chemistry and biology.
- Open Access
- 1 May 2012
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 4 (S1) , P51
How often do follow-on activities occur - trends seen in a patent database for GPCRs
- 1 May 2012
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 4 (S1) , P51
Open AccessHow often do follow-on activities occur - trends seen in a patent database for GPCRs
- Top Cited Papers
- 24 January 2012
- Published by Springer Nature in Nature Chemistry
- Vol. 4 (2) , 90-98
Quantifying the chemical beauty of drugs
Drug-likeness is a key consideration when selecting compounds during the early stages of drug discovery. However, evaluation of drug-likeness in absolute terms does not reflect adequately the whole spectrum of compound quality. More worryingly, widely used rules may inadvertently foster undesirable molecular property inflation as they permit the encroachment of rule-compliant compounds towards their boundaries. We propose a measure of drug-likeness based on the concept of desirability called the quantitative estimate of drug-likeness (QED). The empirical rationale of QED reflects the underlying distribution of molecular properties. QED is intuitive, transparent, straightforward to implement in many practical settings and allows compounds to be ranked by their relative merit. We extended the utility of QED by applying it to the problem of molecular target druggability assessment by prioritizing a large set of published bioactive compounds. The measure may also capture the abstract notion of aesthetics in medicinal chemistry.
- 24 January 2012
- Published by Springer Nature in Nature Chemistry
- Vol. 4 (2) , 90-98
Top Cited PapersQuantifying the chemical beauty of drugs
Drug-likeness is a key consideration when selecting compounds during the early stages of drug discovery. However, evaluation of drug-likeness in absolute terms does not reflect adequately the whole spectrum of compound quality. More worryingly, widely used rules may inadvertently foster undesirable molecular property inflation as they permit the encroachment of rule-compliant compounds towards their boundaries. We propose a measure of drug-likeness based on the concept of desirability called the quantitative estimate of drug-likeness (QED). The empirical rationale of QED reflects the underlying distribution of molecular properties. QED is intuitive, transparent, straightforward to implement in many practical settings and allows compounds to be ranked by their relative merit. We extended the utility of QED by applying it to the problem of molecular target druggability assessment by prioritizing a large set of published bioactive compounds. The measure may also capture the abstract notion of aesthetics in medicinal chemistry.
- 28 December 2011
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 52 (1) , 51-62
Improved Chemical Text Mining of Patents with Infinite Dictionaries and Automatic Spelling Correction
The text mining of patents of pharmaceutical interest poses a number of unique challenges not encountered in other fields of text mining. Unlike fields, such as bioinformatics, where the number of terms of interest is enumerable and essentially static, systematic chemical nomenclature can describe an infinite number of molecules. Hence, the dictionary- and ontology-based techniques that are commonly used for gene names, diseases, species, etc., have limited utility when searching for novel therapeutic compounds in patents. Additionally, the length and the composition of IUPAC-like names make them more susceptible to typographic problems: OCR failures, human spelling errors, and hyphenation and line breaking issues. This work describes a novel technique, called CaffeineFix, designed to efficiently identify chemical names in free text, even in the presence of typographical errors. Corrected chemical names are generated as input for name-to-structure software. This forms a preprocessing pass, independent of the name-to-structure software used, and is shown to greatly improve the results of chemical text mining in our study.
- 28 December 2011
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 52 (1) , 51-62
Improved Chemical Text Mining of Patents with Infinite Dictionaries and Automatic Spelling Correction
The text mining of patents of pharmaceutical interest poses a number of unique challenges not encountered in other fields of text mining. Unlike fields, such as bioinformatics, where the number of terms of interest is enumerable and essentially static, systematic chemical nomenclature can describe an infinite number of molecules. Hence, the dictionary- and ontology-based techniques that are commonly used for gene names, diseases, species, etc., have limited utility when searching for novel therapeutic compounds in patents. Additionally, the length and the composition of IUPAC-like names make them more susceptible to typographic problems: OCR failures, human spelling errors, and hyphenation and line breaking issues. This work describes a novel technique, called CaffeineFix, designed to efficiently identify chemical names in free text, even in the presence of typographical errors. Corrected chemical names are generated as input for name-to-structure software. This forms a preprocessing pass, independent of the name-to-structure software used, and is shown to greatly improve the results of chemical text mining in our study.
- 1 December 2011
- Published by Elsevier in Drug Discovery Today
- Vol. 16 (23-24) , 1019-1030
Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data
- 1 December 2011
- Published by Elsevier in Drug Discovery Today
- Vol. 16 (23-24) , 1019-1030
Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data
- Open Access
- 13 May 2011
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 3 (1) , 14
Analysis of in vitrobioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds
Since the classic Hopkins and Groom druggable genome review in 2002, there have been a number of publications updating both the hypothetical and successful human drug target statistics. However, listings of research targets that define the area between these two extremes are sparse because of the challenges of collating published information at the necessary scale. We have addressed this by interrogating databases, populated by expert curation, of bioactivity data extracted from patents and journal papers over the last 30 years.
- 13 May 2011
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 3 (1) , 14
Open AccessAnalysis of in vitrobioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds
Since the classic Hopkins and Groom druggable genome review in 2002, there have been a number of publications updating both the hypothetical and successful human drug target statistics. However, listings of research targets that define the area between these two extremes are sparse because of the challenges of collating published information at the necessary scale. We have addressed this by interrogating databases, populated by expert curation, of bioactivity data extracted from patents and journal papers over the last 30 years.
- Open Access
- 19 April 2011
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 3 (S1) , O16
Improved chemical text mining of patents using infinite dictionaries, translation and automatic spelling correction
- 19 April 2011
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 3 (S1) , O16
Open AccessImproved chemical text mining of patents using infinite dictionaries, translation and automatic spelling correction
- Open Access
- 4 May 2010
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 2 (S1) , P7
Comparing manual and automated extraction of chemical entities from documents
- 4 May 2010
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 2 (S1) , P7
Open AccessComparing manual and automated extraction of chemical entities from documents
- 1 December 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (24) , 6943-6947
Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds
- 1 December 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (24) , 6943-6947
Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds